Article

May 15, 2004

Allergy agents popular with both physicians and patients

Rapid relief, good safety profile, long-term efficacy are advantages for highly effective drugs

Related Videos

J. Peter Campbell, MD, MPH

Expanding accessibility of vision correction with spectacles for children with cranial abnormalities

Elkin: Talking about the importance of pediatric eye health and safety

Identifying 3 barriers keeping families from accessing cataract treatment for their children in India

Edward Manche, MD

Related Content

4-Year research validates DOT 0.2 spectacle lenses as early myopia treatment

December 12th 2024

4-Year research validates DOT 0.2 spectacle lenses as early myopia treatment

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Early vision screening is key to slowing myopia progression in children

November 28th 2024

Early vision screening is key to slowing myopia progression in children

Managing a changing landscape of IRD pediatric cases

May 10th 2021

Managing a changing landscape of IRD pediatric cases

Alkeus Pharmaceuticals receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as treatment for Stargardt disease

November 18th 2024

Alkeus Pharmaceuticals receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as treatment for Stargardt disease

Cerebral visual impairment is a growing concern in pediatric vision loss

November 14th 2024

Cerebral visual impairment is a growing concern in pediatric vision loss

Related Content

4-Year research validates DOT 0.2 spectacle lenses as early myopia treatment

December 12th 2024

4-Year research validates DOT 0.2 spectacle lenses as early myopia treatment

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Early vision screening is key to slowing myopia progression in children

November 28th 2024

Early vision screening is key to slowing myopia progression in children

Managing a changing landscape of IRD pediatric cases

May 10th 2021

Managing a changing landscape of IRD pediatric cases

Alkeus Pharmaceuticals receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as treatment for Stargardt disease

November 18th 2024

Alkeus Pharmaceuticals receives FDA Rare Pediatric Disease and Fast Track designations for gildeuretinol as treatment for Stargardt disease

Cerebral visual impairment is a growing concern in pediatric vision loss

November 14th 2024

Cerebral visual impairment is a growing concern in pediatric vision loss

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.